This site is intended for Healthcare Professionals only
migraine-aura-1280
bookmark icon off

Research roundup 2 - November

Mark Greener reports on nail disorders with GLP-1 receptor agonists, a urine test for bladder cancer, night-time light and heart health, and lamotrigine for migraine aura

Nailing GLP-1 side-effects
GLP-1RAs may increase the risk of nail disorders, according to a multi-national, cross-sectional study presented during the European Academy of Dermatology and Venereology Congress in Vienna.
Researchers in France, the US, Brazil and Mexico compared 575 people taking GLP-1RAs with 1,329 controls who had never taken these drugs. All participants had type 2 diabetes, obesity or both. Patients received GLP-1RAs for an average of 18.5 months.
Overall, 66.3% of GLP-1RA users and 52.8% of controls experienced at least one nail disorder. For example, nail detachment was seven times more common among GLP-1RA users than controls (39.3% and 8.7% respectively; odds ratio [OR] 6.84).
Dyschromia was four times more common among GLP-1RA users than controls (45.6% and 17.0% respectively; OR 4.09). Onycholysis (OR 2.29), ridges/grooves (OR 1.89) and fragility (OR 1.34) were also more common among those receiving GLP-1RAs.
The differences remained significant when the analysis included only patients who lost weight, so weight loss alone does not account for the increased nail problems. Adjusting for dermatological conditions and nutritional deficiencies reduced the strength of some associations. However, nail detachment and discolouration were still two to three times more common among GLP-1RA users than controls.
“Until now, nail changes associated with GLP-1 therapies had essentially been anecdotal,” says study author Charles Taïeb, European Market Maintenance Assessment, Paris, France.
“Our findings show a clear association, but they also underline an important point: not everything that happens during GLP-1 treatment is necessarily caused by the treatment itself.”
Urine test for bladder cancer
Bladder cancer is the 11th most common malignancy and the ninth most common cause of cancer death in the UK. Now US researchers report that a urine test can diagnose bladder cancer more accurately than current methods.
Increasingly, cancer specialists use small pieces of DNA released into the blood (circulating tumour DNA) as cancer cells die to diagnose malignancies, and guide and monitor treatment.
However, normal cells lining the bladder often accumulate mutations that overlap with those in the cancer. DNA tests can mistake these ‘bystander mutations’ for malignancy. So, the tumour and normal tissue are sequenced to identify which mutations to track.
The new test measures circulating cell-free RNA (cfRNA), which reflects overall gene activity. “You’re looking for a biological signature of disease, not an exact likeness, and urine is a non-invasive way to accurately detect and track bladder cancer,” says Professor Ash Alizadeh, Stanford University. Researchers tested 683 urine samples from patients with cancer and controls. The test showed 95% sensitivity and 90% specificity for detecting localised bladder cancer.
In other words, urine cfRNA correctly identified 95% of people with localised bladder cancer and correctly cleared 90% of those without. It outperformed standard urine cytology and a DNA-based urine test.
Urine cfRNA also identified residual cancer after surgery and Bacillus Calmette-Guérin (BCG) immunotherapy, and revealed a pattern of changes that identified people likely to respond to BCG.
Nature Medicine DOI: 10.1038/s41591-026-04673-3
Darkness: a ‘vital sign’ for CV health
Nocturnal light exposure is linked to cardiovascular disease (CVD) and potentially harmful changes in the heart’s structure and function, according to researchers who followed 73,286 UK Biobank participants for 8–10 years.
“This is the first study of its kind and it shows that exposure to higher levels of light at night-time is linked to cardiac remodelling,” says study leader Professor Lu Qi, Tulane University, New Orleans. An accompanying editorial concludes that darkness is “a vital sign, as essential to cardiovascular health as blood pressure control and clean air”.
People exposed to more than 3 lux of light during the night (a candle at one metre produces about 1 lux) were more likely to experience stroke (by 33%), heart failure (29%), CVD death (26%), myocardial infarction (24%) and atrial fibrillation (15%) than people with almost no night-time light exposure.
In addition, 11,071 people wore wrist light sensors for seven days and underwent magnetic resonance imaging three years later. Adjusting for confounders, night-time light above 3 lux was associated with thickening of the left ventricle and reduced flexing of the heart during heartbeats. The right ventricle and left atria also showed potentially harmful changes.
Shorter sleep duration accounted for 24–49% of the changes to the heart’s structure and function. The changes and the increased CVD risk were more marked as nocturnal light intensity rose.
“Our findings, together with evidence from other studies, suggest that reduction of night-time light exposure should be considered as one of the potential strategies for preventing heart disease by clinicians and policy makers,” Qi concludes.
European Heart Journal DOI: 10.1093/eurheartj/ehag563 and 10.1093/eurheartj/ehag650
Lamotrigine reduces migraine aura
Lamotrigine reduces the frequency of migraine aura by 80%, Swedish scientists report. There is no established treatment that specifically targets aura, and migraines with and without aura are often treated in a similar way, says study author Gürdal Sahin of Lund University.
The retrospective study included 81 patients, 67.9% of whom were women. Most (98.7%) reported visual aura, while 45.6% experienced sensory aura, 32.0% speech and/or language disturbances and 9.8% extreme photosensitivity.
Reaching the average maintenance dose of 149.6mg took a median of 11 months, and treatment lasted a median of 44 months.
Lamotrigine prophylaxis reduced the mean number of monthly aura days from 6.9 to 1.4, a 79.7% reduction. Overall, 85.2% of participants reported at least a 50% reduction in monthly aura days.
Twenty-nine (35.8%) patients experienced adverse events: 14 reported skin-related changes such as rash and hair loss, and 11 cognitive changes including dizziness and impaired concentration.
Five discontinued lamotrigine because of side-effects and one experienced visual hallucinations of insects.
The study authors are now proceeding with a randomised, double-blind, placebo-controlled trial of lamotrigine.
Frontiers in Neurology DOI: 10.3389/fneur.2026.1863747

Share:

Change privacy settings